Immunovaccine and Leidos Expand Collaboration to Develop Malaria Vaccines Formulated in DepoVax™
“We are very encouraged by what
The USAID MVDP project aims to evaluate malaria vaccine candidates in the preclinical, clinical, and field stages of development. Research performed under the collaboration with
In 2016, the
USAID invests in research and development of malaria vaccines and new antimalarial drugs and insecticide-based vector control tools. USAID research and development programs are aimed at identifying the most promising targets and vaccine formulations
The technology underlying DepoVax formulations suspends active components in an oil diluent that prevents their release at the site of injection. This process forces immune cells to take up these components in an active process, delivering them directly to immune organs such as the lymph nodes. DepoVax formulations have undergone extensive testing in more than 60 preclinical and seven clinical studies. In clinical trials, these formulations have consistently demonstrated the ability to generate robust T and B cell responses, and durable immune responses.
Immunovaccine Forward-Looking Statements
This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on thedate the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals.
T: (312) 961-2503 E: email@example.com
Pierre Labbé, Chief Financial Officer
T: (581) 741-6639 E: firstname.lastname@example.org
O: (415) 513-1284
T: (415) 515-4572 E: email@example.com
Source: Immunovaccine Inc.